Syndax and Royalty Pharma finalize $350 million deal

6 November 2024

Syndax Pharmaceuticals (Nasdaq: SNDX) has entered into a $350 million royalty funding agreement with Royalty Pharma (Nasdaq: RPRX).

The deal is focused on US net sales of Niktimvo (axatilimab-csfr), an approved treatment for chronic graft-versus-host disease. The agreement includes a 13.8% royalty on US sales, which will end once Royalty Pharma receives a 2.35 times return on its investment.

The partnership comes amid strong growth for Royalty Pharma, which recently reported a 12% rise in portfolio receipts in the second quarter, beating its high-single-digit forecast. The firm has committed $2 billion in royalty acquisitions and recently increased its 2024 guidance, projecting portfolio receipts to exceed $2.7 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical